-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3c9183dd-26ed-465b-9e7d-92692ff5cc54&Preview=1 -
Date
5/16/2012 -
Company Name
Mitralign -
Mailing Address
3 Highwood Drive Tewksbury, MA 01876 -
Company Description
We are currently developing an innovative, catheter-based mitral valve repair system that not only provides an alternative to open heart surgery but emulates the traditional surgical repair technique.The condition treated, mitral valve regurgitation (MR), is common in patients with Congestive Heart Failure. Clinical studies have proven that MR significantly increases the risk of mortality in patients afflicted with CHF, a disease affecting 25 Million worldwide. Studies hence recommend earlier treatment of MR in these patients.
-
Website
http://www.mitralign.com -
Transaction Type
Venture Equity -
Transaction Amount
$35,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds from the Series D financing will support completing the CE Mark study, securing the CE Mark, and initiating sales in the EU. -
M&A Terms
-
Venture Investor
Forbion Capital Partners -
Venture Investor
Saints Capital -
Venture Investor
Oxford Bioscience Partners -
Venture Investor
Triathlon Medical Ventures -
Venture Investor
Medtronic -
Venture Investor
Johnson & Johnson Development Corporation -
Venture Investor
Oakwood Medical Investors -
Venture Investor
Palisade Capital Management -
Venture Investor
Giza Capital